← Oncology Approval Tracker

FDA DECISION ·

Niktimvo

axatilimab-csfr · Incyte

FDA approvalNew therapyChronic graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and children weighing at least 40 kg with chronic graft-versus-host disease after failure of two or more prior systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The CSF-1 receptor antibody adds a treatment for chronic GVHD after multiple systemic therapies have failed.

What research teams should watch

Verify prior therapy failure, record organ-specific baseline scores and coordinate review of lab changes and infusion reactions.

PRIMARY RECORDS

Sources